Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide, polypeptide-modified lipid carrier and application of lipid carrier

A technology of lipid carrier and liposome, which is applied in the field of polypeptide-modified lipid carrier and polypeptide, can solve the problems of reducing phagocytosis of macrophages, low clinical value, and difficult production, so as to improve delivery in vivo, inhibit phagocytosis, The effect of reducing the distribution

Active Publication Date: 2019-12-06
SOUTHWEST UNIVERSITY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, nanomedicine preparations with CD47 can significantly reduce the phagocytosis of macrophages, but as a complete protein, CD47 is not easy to produce and has little clinical value, so the applicant refers to the research of Rodriguez et al [Rodriguez P L, Harada T, Christian D A , et al.Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles[J].Science,2013,339(6122):971-975.], they screened out the active site of CD47 and named it "Self" Peptide, and then demonstrated that polystyrene nanoparticles labeled "Self" peptide exhibited the same anti-phagocytosis effect as CD47

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide, polypeptide-modified lipid carrier and application of lipid carrier
  • Polypeptide, polypeptide-modified lipid carrier and application of lipid carrier
  • Polypeptide, polypeptide-modified lipid carrier and application of lipid carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] The implementation mode of linking cholesterol to polypeptide is according to literature [Ingallinella P, Bianchi E, Ladwa NA, et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibits dramatically increases its antiviral potency. Proceedings of the National Academy of Sciences, 2009, 106( 14): 5801-5806.] Carry out, specifically, obtain polypeptide C by solid-phase synthesis D GK D L D E. D I D V D T D K D GE D R D S D L D E. D T D V D E. D C D T D Y D N D G. Dissolve 100 mg of cholesterol (injection grade, purchased from Everett Company) and 40 mg of bromoacetic acid (purity greater than 99%, purchased from Adamas) in 1500 μL of anhydrous dichloromethane (purchased from Sigma Company), and add 44 μL of N, N'-diisopropylcarbodiimide (98%+, purchased from Adamas) and 1.5mg 4-dimethylaminopyridine (99%, purchased from Adamas) were used as catalysts, stirred at 400rpm at room temperature for 48h, then reduced Dry under pressure to obtai...

Embodiment 2

[0041] Both L-type "Self" peptide (LMS) and D-type "Self" peptide (DMS) are synthesized by solid-phase synthesis, wherein the specific sequence of LMS is as follows: GNYTCEVTELSREGKTVIELK (as shown in SEQ ID NO.1), and in the amino The segment is synthesized by solid phase [Cao L, Fischer A, Bornscheuer U T, et al. Lipase-Catalyzed Solid Phase Synthesis of Sugar Fatty Acid Esters. Biocatalysis, 1996, 14(4): 15.] Adding palmitic acid, the specific sequence of DMS is as follows : GK D L D E. D I D V D T D K D GE D R D S D L D E. D T D V D E. D C D T D Y D N D G, and add palmitic acid at the amino segment by solid-phase synthesis.

[0042] The two configurations of polypeptides were prepared as 5 mg / ml solutions in PBS, and mouse serum (Abbkine) was added to RPMI 1640 to obtain solution A containing 25% (volume ratio) of mouse serum. Add the peptide solution to solution A to a final peptide concentration of 100 μg / ml. Incubate at 37°C for 0.5, 1, 2, 4, 8, and ...

Embodiment 3

[0044]Polypeptide solution (1 mg / ml) was prepared in methanol, egg yolk lecithin (PL-100m, Ivet) solution (28 mg / ml) was prepared in ethanol, cholesterol (injection grade, purchased from Ivet) was prepared in chloroform Special) solution (12mg / ml). The phospholipid, cholesterol and polypeptide solutions were mixed at 500:250:40 (volume ratio) to obtain about 2ml of mixed solution. Evaporate to dryness under reduced pressure to obtain a phospholipid film, and remove a small amount of organic solvent with nitrogen gas. PBS solution (pH = 7.2) was added to the film and shaken in a constant temperature water bath at 37° C. to obtain multilamellar liposomes. The liposomes were respectively passed through liposome extruders containing 400nm, 200nm and 100nm polycarbonate membranes for 20 times each to obtain the desired polypeptide liposomes, which were stored for future use.

[0045] RAW264.7 cells in the logarithmic growth phase (purchased from the Shanghai Cell Bank of the Chin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to a polypeptide, a polypeptide-modified lipid carrier and application of the lipid carrier as a medicament for inhibiting phagocytosis of macrophages. The invention provides a method capable of enabling the lipid carrier to be adhered to the surface of macrophage cell membrane for a long time so as to promote the delivery of nanoparticles in vivo based on the fact that a nano preparation is easy to be phagocytosed and metabolized by macrophages during the in-vivo delivery. After "Self" D-type polypeptide and phospholipid or other materials form a lipid carrier, when thelipid carrier reacts with the macrophages, the lipid carrier can stay on the surface of the macrophages for a long time so as to inhibit the phagocytosis of the macrophages and to improve the in-vivodelivery of the nano carrier remarkably. The lipid carrier of the invention can be adhered to the surface of the macrophage, promote the phosphorylation of SIRP alpha protein of the macrophages, and inhibit the phagocytosis of the macrophages. After entering the body, the carrier can inhibit phagocytosis of the macrophages and prolong the in-vivo half-life of a subsequently-injected medicament. The research of the invention shows that by administering the lipid carrier, the half-life of the nano preparation in vivo can be obviously prolonged, and the distribution of medicament in liver and spleen can be reduced.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a polypeptide, a lipid carrier modified by the polypeptide and applications thereof. Background technique [0002] The concept of macrophage blockade or reticuloendothelial blockade (RES blockade) was proposed in 1969 [Saba T M, Di L N. Reticuloendothelial blockade and recovery as a function of opsonic activity. American Journal of Physiology, 1969, 216 (216): 197-205.], because this strategy realizes the long circulation process is simple, does not change the existing preparation form, and was widely studied in the 1980s, Proffitt et al [Proffitt R T, Williams L E, Presant C A, et al .Liposomal blockade of the reticuloendothelial system:improved tumor imaging with small unilamellar vesicles.Science.1983,220(4596):502-505.] The reticuloendothelial system was closed, and then the liposomes labeled with radioactive elements were used for localization in vivo. It was found that compared ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/705A61K9/127A61K47/42A61K47/24A61K47/28A61K47/44A61K47/10
CPCA61K9/127A61K47/10A61K47/24A61K47/28A61K47/42A61K47/44C07K14/70503
Inventor 李翀唐宜轩于洋
Owner SOUTHWEST UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com